false 0001962011 0001962011 2025-06-10 2025-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 10, 2025

 

Kairos Pharma, Ltd.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42275   46-2993314

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2355 Westwood Blvd., #139

Los Angeles CA 90064

(Address of principal executive offices) (Zip Code)

 

(310) 948-2356

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol (s)   Name of each exchange on which registered
Common Stock, par value $0.001, per share   KAPA   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On June 10, 2025, Kairos Pharma, Ltd., a Delaware corporation (the “Company”), entered into a services agreement (the “Services Agreement”) with Barretto Pacific Corporation (“BPC”) pursuant to which BPC agreed to provide certain services, including, disseminating public information about the Company, its business and affairs, communicating on an ongoing basis with members of the brokerage and investment community in the U.S., identifying investor conferences where the Company’s management may be invited to attend, and reviewing the Company’s proposed news releases, among other things. BPC will provide services for a one year period in exchange for a services fee of $170,000, which will be paid in monthly increments. The Services Agreement also contains other customary clauses, including expense reimbursement, indemnification, term and termination, and governing law clauses.

 

The foregoing summary of the terms and conditions of Services Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement, which is attached hereto as Exhibits 10.1 and is incorporated by reference herein.

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On June 10, 2025, Kairos Pharma Ltd., a Delaware corporation (the “Company”), held its annual meeting of stockholders (the “Annual Meeting”) to vote on the following matters:

 

1. Election of Directors.

 

All of the following four nominees were elected to the Company’s board of directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.

 

Nominee  For  Against  Withheld  Broker Non-Votes
John S. Yu, M.D.  10,378,376  0  23,773  1,100,419
Hyun W. Bae, M.D.  10,377,019  0  25,130  1,100,419
Hansoo Michael Keyoung, M.D., Ph.D.  10,378,376  0  23,773  1,100,419
Rahul Sighvi, Sci.D., MBA  10,378,375  0  23,774  1,100,419

 

2. Ratification of the Company’s Independent Auditors.

 

Stockholders ratified the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, in accordance with the voting results below.

 

For   Against   Abstain   Broker Non-Votes  
11,130,850   31,741   339,977   -  

 

3. Approval of the Company’s Executive Compensation.

 

Stockholders approved (on an advisory basis) the Company’s executive compensation.

 

For   Against   Abstain   Broker Non-Votes  
10,022,900   16,834   362,415   1,100,419  

 

4. Approval of the frequency of voting on the Company’s executive compensation.

 

Stockholders approved the advisory vote on conducting advisory votes on executive compensation once every year.

 

    For   Abstain   Broker Non-Votes  
1 Year   10,040,885   339,673   -  
2 Years   7,833   339,673   -  
3 Years   13,758   339,673   -  

 

5. Approval of the Issuance of in Excess of 20% of the Company’s Common Stock at A Price Below “Minimum Price” in Compliance with Section 713 of The NYSE American LLC Company Guide.

 

Stockholders approved the issuance of in excess of 20% of the Company’s common stock at a price below “minimum price” in compliance with section 713 of the NYSE American LLC Company Guide.

 

For   Against   Abstain   Broker Non-Votes  
10,765,370   623,989   113,209   -  

 

 
 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

No.

  Description
     
99.1   Services Agreement, dated June 10, 2025, between Kairos Pharma Ltd and the Company and Barretto Pacific Corporation.
104   Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 12, 2025 KAIROS PHARMA, LTD.
     
  By: /s/ John S. Yu
    John S. Yu
    Chief Executive Officer